General Psychiatry - Articles - Page 146

Drug-Drug Interactions

February 1, 2011

Neil Sandson, MD. Clinical associate professor, Department of Psychiatry, University of Maryland School of Medicine; Staff psychiatrist, VA Maryland Health Care System.
Dr. Sandson has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.educational activity.

It seems that drug-drug interactions (DDI) were in our profession’s consciousness more in the past than they are now. Is this because we have less to worry about than we used to?

Atypicals No Better Than Typicals in Depression with Schizophrenia

February 1, 2011

Second generation antipsychotics have developed a reputation for being more effective for treating a number of the symptoms of schizophrenia than their first generation counterparts, even if research doesn’t always back up this claim.

Should We Give Patients the Treatment They Request?

February 1, 2011

Since antidepressants and psychotherapy are about equally effective for mild to moderate depression, how do we decide which to use for a given patient?

Learning Objectives, Drug-Drug Interactions, TCPR, February 2011

February 1, 2011

After reading these articles, you should be able to…

Using Lithium in Bipolar Disorder: A Primer

January 1, 2011

Currently, lithium is FDA approved for both acute mania and for maintenance bipolar treatment, but not for bipolar depression. Lithium is dirt-cheap and the size of its database for efficacy in bipolar disorder is unmatched by any other medication, although many of these studies are old.

Discussing Bipolar Disorder with Your Patients

January 1, 2011

In my experience, there are five common reactions from patients with a new diagnosis of bipolar disorder, and here are some suggestions for how to respond constructively.

Distinguishing Bipolar from Unipolar Depression

January 1, 2011

Ross Baldessarini, MD

Ross Baldessarini, MD Professor of psychiatry and neuroscience, Harvard Medical School, Boston, MA; Director, psychopharmacology program & International Consortium for Bipolar Disorder Research, McLean Hospital, Belmont, MA Dr. Baldessarini has disclosed that he has recently been a paid consultant to Alkermes, Inc., a comarketer of Risperdal Consta and VIVITROL (a monthly injectable form of naloxone for alcohol and opioid dependence). Dr. Carlat reviewed this article and found that there is no evidence of commercial bias in this educational activity.

Some patients complain bitterly about depression and dysphoria, but they don’t tell you anything about the other half of their lives—the upswings of mood and energy—so you may not realize the need to suspect bipolar illness.

Vascular Depression? Not so Fast.

January 1, 2011

More than a decade ago, researchers introduced the concept of “vascular depression,” a specific type of depression associated with cerebrovascular disease and loss of blood to the brain in older adults.

Adjunctive Nuvigil Possibly Effective for Bipolar Depression

January 1, 2011

The treatment of bipolar depression remains challenging. Only two medications are FDA approved for the condition—quetiapine (Seroquel) and olanzapine (Zyprexa)/fluoxetine (Prozac) combination—both of which cause weight gain and sedation, among other side effects.

General Psychiatry
RSS

Drug-Drug Interactions

Atypicals No Better Than Typicals in Depression with Schizophrenia

Should We Give Patients the Treatment They Request?

Learning Objectives, Drug-Drug Interactions, TCPR, February 2011

Using Lithium in Bipolar Disorder: A Primer

Discussing Bipolar Disorder with Your Patients

Distinguishing Bipolar from Unipolar Depression

Vascular Depression? Not so Fast.

Adjunctive Nuvigil Possibly Effective for Bipolar Depression

Learning Objectives, Bipolar Disorder, TCPR, January 2011

Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

Hidden Gems: Pramipexole Part II

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

About

Shop Online

Newsletters

Contact

Follow Us

General Psychiatry RSS

About

Shop Online

Newsletters

Contact

Follow Us

General Psychiatry
RSS